NEW YORK, NY / ACCESSWIRE / August 10, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Churchill Capital Corp IV (NYSE:CCIV)
If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/churchill-capital-corp-iv-loss-submission-form?prid=18418&wire=1
Lead Plaintiff Deadline: August 30, 2021
Class Period: January 11, 2021 - February 22, 2021
Allegations against CCIV include that: (1) Lucid was not prepared to deliver vehicles by spring of 2021; (2) Lucid was projecting a production of 557 vehicles in 2021 instead of the 6,000 vehicles touted in the run-up to the merger with Churchill; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
CorMedix Inc. (NASDAQ:CRMD)
If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/cormedix-inc-loss-submission-form?prid=18418&wire=1
Lead Plaintiff Deadline: September 20, 2021
Class Period: July 8, 2020 - May 13, 2021
Allegations against CRMD include that: (i) deficiencies existed with respect to an investigational drug product, DefenCath's, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
AdaptHealth Corp. f/k/a DFB Healthcare Acquisitions Corp. (NASDAQ:AHCO)
If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/adapthealth-corp-f-k-a-dfb-healthcare-acquisitions-corp-loss-submission-form?prid=18418&wire=1
Lead Plaintiff Deadline: September 27, 2021
Class Period: November 11, 2019 - July 16, 2021
Allegations against AHCO include that: (i) AdaptHealth had misrepresented its organic growth trajectory by retroactively inflating past organic growth numbers without disclosing the changes, in violation of Securities and Exchange Commission regulations; (ii) accordingly, the Company had materially overstated its financial prospects; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com:
https://www.accesswire.com/659186/SHAREHOLDER-ALERT-CCIV-CRMD-AHCO-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines
